Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 10;59(1):133.
doi: 10.3390/medicina59010133.

Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center

Angelo Mottaran  1   2 , Amelio Ercolino  1   2 , Lorenzo Bianchi  1   2 , Pietro Piazza  1   2 , Francesco Manes  1   2 , Sasan Amirhassankhani  1   2 , Marco Salvador  1   2 , Francesco Chessa  1   2 , Beniamino Corcioni  1   3 , Alessandro Bertaccini  1   2 , Riccardo Schiavina  1   2 , Eugenio Brunocilla  1   2
Affiliations
Review

Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center

Angelo Mottaran et al. Medicina (Kaunas). .

Abstract

Background and Objectives: The aim of this article is to present a single-surgeon, open retroperitoneal lymph node dissection (RPLND) series for testicular cancer in a high-volume center. Materials and Methods: We reviewed data from patients who underwent RPLND performed by an experienced surgeon at our institution between 2000 and 2019. We evaluated surgical and perioperative outcomes, complications, Recurrence-Free Survival (RFS), Overall Survival (OS), and Cancer-Specific Survival (CSS). Results: RPLND was performed in primary and secondary settings in 21 (32%) and 44 (68%) patients, respectively. Median operative time was 180 min. Median hospital stay was 6 days. Complications occurred in 23 (35%) patients, with 9 (14%) events reported as Clavien grade ≥ 3. Patients in the primary RPLND group were significantly younger, more likely to have NSGCT, had higher clinical N0 and M0, and had higher nerve-sparing RPLND (all p ≤ 0.04) compared to those in the secondary RPLND group. In the median follow-up of 120 (56-180) months, 10 (15%) patients experienced recurrence. Finally, 20-year OS, CSS, and RFS were 89%, 92%, and 85%, respectively, with no significant difference in survival rates between primary vs. secondary RPLND subgroups (p = 0.64, p = 0.7, and p = 0.31, respectively). Conclusions: Open RPLND performed by an experienced high-volume surgeon achieves excellent oncological and functional outcomes supporting the centralization of these complex procedures.

Keywords: RPLND; open approach; primary setting; retroperitoneal lymph node dissection; secondary setting; surgical volume; testicular cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Inclusion and exclusion criteria.
Figure 2
Figure 2
Overall and mixed distribution of testicular cancer histotypes at post-orchiectomy pathology.
Figure 3
Figure 3
Overall and mixed distribution of testicular cancer histotypes at post-RPLND pathology.
Figure 4
Figure 4
Bilateral RPLND template with inferior mesenteric artery dissection.
Figure 5
Figure 5
Radical nephrectomy during retroperitoneal lymph node dissection.
Figure 6
Figure 6
Kaplan–Meier Curve for Overall Survival (A) and Recurrence-Free Survival (B) of patients with testicular cancer and submitted to RPLND.
Figure 7
Figure 7
Kaplan–Meier with log-rank test for comparison of Overall Survival (A) and Recurrence-Free Survival (B) between primary and secondary RPLND subgroups patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Schwen Z.R., Gupta M., Pierorazio P.M. A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer. Adv. Urol. 2018;2018:2146080. doi: 10.1155/2018/2146080. - DOI - PMC - PubMed
    1. Reese S.W., Tully K.H., Nabi J., Paciotti M., Chou W.H., Trinh Q.D. Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades. Eur. Urol. Oncol. 2021;4:834–836. doi: 10.1016/j.euo.2020.06.011. - DOI - PubMed
    1. Crocetto F., Arcaniolo D., Napolitano L., Barone B., la Rocca R., Capece M., Caputo V.F., Imbimbo C., de Sio M., Calace F.P., et al. Impact of Sexual Activity on the Risk of Male Genital Tumors: A Systematic Review of the Literature. Int. J. Environ. Res. Public Health. 2021;18:8500. doi: 10.3390/ijerph18168500. - DOI - PMC - PubMed
    1. Nicolai N., Tarabelloni N., Gasperoni F., Catanzaro M., Stagni S., Torelli T., Tesone A., Bettin L., Necchi A., Giannatempo P., et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. J. Urol. 2018;199:741–747. doi: 10.1016/j.juro.2017.09.088. - DOI - PubMed
    1. Tandstad T., Smaaland R., Solberg A., Bremnes R.M., Langberg C.W., Laurell A., Stierner U.K., Ståhl O., Cavallin-Ståhl E.K., Klepp O.H., et al. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study from the Swedish Norwegian Testicular Cancer Study Group. J. Clin. Oncol. 2011;29:719–725. doi: 10.1200/JCO.2010.30.1044. - DOI - PubMed

Supplementary concepts